Suppr超能文献

依折麦布:整合既有应用与新证据——全面综述。

Ezetimibe: Integrating Established Use with New Evidence - A Comprehensive Review.

机构信息

Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DiSFeB), University of Milan, Milan, Italy.

IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy.

出版信息

Curr Atheroscler Rep. 2024 Nov 25;27(1):10. doi: 10.1007/s11883-024-01248-w.

Abstract

PURPOSE OF REVIEW

To consolidate key information on the efficacy and safety of ezetimibe, with a focus on the latest evidence.

RECENT FINDINGS

While ezetimibe has long been used alongside statins to help achieve lipid goals when statins are insufficient or in statin-intolerant patients, recent studies confirm and extend its benefits. Ezetimibe, when added to statins, is now recognized as an effective option for high-risk cardiovascular patients. Additionally, for those intolerant to statins, it can be combined with bempedoic acid, offering significant LDL cholesterol reduction. Ezetimibe's favourable tolerability, with fewer side effects than statins, along with the availability of fixed-dose combinations, enhances both treatment efficacy and patient adherence. Overall, this review underscores ezetimibe's evolving role in lipid management, providing valuable guidance for optimizing cardiovascular risk reduction strategies.

摘要

目的综述

总结依折麦布在疗效和安全性方面的关键信息,重点关注最新证据。

最新发现

依折麦布长期以来一直与他汀类药物联合使用,以帮助在他汀类药物不足或他汀类药物不耐受患者中实现血脂目标,最近的研究证实并扩展了其益处。依折麦布联合他汀类药物,现在被认为是心血管高危患者的有效选择。此外,对于那些不能耐受他汀类药物的患者,它可以与贝匹地酸联合使用,显著降低 LDL 胆固醇。依折麦布的耐受性良好,副作用比他汀类药物少,并且有固定剂量组合,提高了治疗效果和患者的依从性。总的来说,本综述强调了依折麦布在血脂管理中的不断发展的作用,为优化心血管风险降低策略提供了有价值的指导。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验